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ABSTRACT
Microtubule-associated protein 2 (MAP2), a neuron-
specific protein, stabilizes microtubules and is
critical for neurite outgrowth and dendrite develop-
ment. Although MAP2 is widely used as a marker of
neuronal differentiation, regulation of its transcrip-
tion has not been investigated. We showed that
MAP2 is frequently activated in human cutaneous
melanoma. Here, we identified a 2.2 kb region that is
sufficient for neuronal-specific expression in vitro
and in vivo. Comparative analysis of the mouse, rat
and human MAP2 promoter sequences showed the
presence of a conserved bHLH factor binding sites.
Electrophoretic mobility shift analysis, promoter
mutagenesis and co-transfection experiments
showed that NeuroD, a pro-neuronal differentiation
factor, and Hairy and Enhancer of Split (HES1), a
transcription repressor, are involved in the regula-
tion of MAP2 promoter activity. Melanoma cells
express both NeuroD and HES1. Chromatin
immunoprecipitation showed that in metastatic
melanoma cells N-box region of the MAP2 promoter
is occupied by endogenous HES1. We show that the
inhibition of Notch signaling, a regulator of HES1
gene expression, and/or shRNA knockdown of HES1
results in the upregulation of MAP2 promoter
activity. Thus, our data suggest that Notch signal-
ing, which is implicated in melanoma progression,
and HES1 play a role in MAP2 gene regulation
during melanoma progression.
INTRODUCTION
Microtubule dynamics is regulated by a family of proteins
known as microtubule-associated proteins (MAPs). MAP
family includes several isoforms of MAP1, MAP2 and tau,
which are expressed primarily in neurons. Among neuronal
MAPs, MAP2 expression is considered a hallmark of neuro-
nal differentiation (1,2). MAP2 is found primarily in the
dendritic extensions of post-mitotic, terminally differentiated
neurons. MAP2 plays a critical role in neurite outgrowth and
dendrite development (3–5). Change in the expression of
MAP2 is a helpful diagnostic and prognostic feature in
various neurological disorders (6–8). Despite its extensive
use as a marker of neuronal differentiation, and its role in
morphological and functional differentiation of neurons, little
is known about the regulation of MAP2 gene expression.
Interestingly, MAP2 gene is activated in certain human
non-neuronal cancers that exhibit characteristics of neural
differentiation (2,9,10). We showed that cutaneous primary
melanoma, a cancer that arises from neural crest-derived
melanocytes, often express abundant MAP2 protein (11).
Since the only function of MAP2, known to date, is to stabi-
lize microtubules, we investigated whether MAP2 expression
in rapidly proliferating cancer cells could interfere with
microtubule dynamics, inhibit mitosis and, therefore, delay
or inhibit tumor progression. We showed, in a ﬁve-year
clinical follow-up study, that patients whose primary tumors
express abundant MAP2 had longer disease-free survival rate
than those patients with weak or no MAP2 expression (12).
Moreover, we showed that reactivation of endogenous
MAP2 gene transcription by treatment with pharmacological
compounds or expression of exogenous MAP2 by adenovirus
in metastatic melanoma cells in vitro leads to cell cycle
arrest, growth inhibition and apoptosis (11,12). These obser-
vations suggested that reactivation of MAP2 gene transcrip-
tion is potentially a useful strategy for the treatment of
metastatic melanoma.
In this study, we show that a 3.3 kb 50 genomic region of
human MAP2 gene that contains several E- and N-boxes,
which are binding sites for basic helix–loop–helix (bHLH)
transcription factors, is sufﬁcient for neuronal-speciﬁc
expression of a reporter gene both in vitro and in vivo.W e
also show that MAP2 promoter is activated by neurogenic
bHLH factor NeuroD/BETA2, preferentially, in melanoma
cells and repressed by the bHLH repressor Hairy and
Enhancer of Split 1 (HES1), a regulator of neuronal differen-
tiation. Although both NeuroD and HES1 are expressed in
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chromatin immunoprecipitation experiments suggest that
MAP2 gene is regulated by the relative levels of these factors,
and predominantly by the level of HES1 protein. Using
HES1shRNA knockdown and a pharmacological inhibitor
of HES1 activator Notch1, we show that MAP2 promoter
activity is regulated by Notch1. We also show that Notch1
signaling, which is implicated in melanoma progression
(13–15), differentially regulates MAP2 promoter activity in
primary and metastatic melanoma cells.
MATERIALS AND METHODS
Cell culture
Mouse neuroblastoma cell line, Neuro2a, and human
embryonal carcinoma cell line NT2-D1 were purchased
from American Type Culture Collection (Manassas, VA).
Neuro2a cells were grown in minimal essential medium
(MEM). The human glioblastoma cell lines U251, U138
and rat PC12 cells were cultured in Rosewell Park Memorial
Institute (RPMI) medium and DMEM, respectively. The
human breast cancer cell line MCF-7 was cultured in MEM
supplemented with bovine insulin. Human ﬁbroblast cell
line NIH3T3 was cultured in DMEM with high glucose,
and human embryonic teratocarcinoma cell line NT2-D1
was cultured in DMEM with high glucose and supplemented
with NaHCO3 (1.5 g/l). Neonatal foreskin melanocytes,
primary melanoma cell lines WM35 and WM75, and
metastatic melanoma cell lines SK-MEL-19, 451Lu and
SK-MEL-23 cl.22a were cultured as described previously
(16). All culture media were supplemented with 10% fetal
bovine serum (FBS). Medium for PC12 cells were supple-
mented with 5% FBS and 10% horse serum, 1% L-glutamine,
and 1% penicillin and streptomycin. All cell culture media,
L-glutamine, penicillin and streptomycin, non-essential
amino acids were from GIBCO (Grand Island, NY), and
FBS was from Sigma (St Louis, MO) or Atlanta Biologicals
(Lawrenceville, GA).
Differentiation of PC12 cells
Before differentiation, cells were grown in 1% horse serum
containing media on collagen-coated tissue culture dishes.
After the cells got attached, they were treated with 100 ng/
ml nerve growth factor (NGF 2.5S; Promega, Madison,
WI). Twenty-four hours after NGF treatment, cells were
transfected with promoter constructs and cultured for addi-
tional 48 h in medium containing NGF. For MAP2 immuno-
staining, PC12 cells were treated with 100 ng/ml NGF for
6 days (17,18).
Plasmids and antibodies
pCI-Hes1, a mouse Hes1 expression plasmid and Hes1 anti-
body (19) were gifts from Prof. R. Kageyama (Institute for
Virus research, Kyoto University, Kyoto, Japan). Rabbit
polyclonal antibody directed against the C-terminal region
of rat Hes1 for supershift experiments was kindly provided
by Dr Y. N. Jan (University of California, San Francisco,
CA). NeuroD expression plasmid pCDNA3-NeuroD1-FLAG
(pNeuroD) (20) was provided by Dr Haeyoung Suh-Kim
(Ajou University School of Medicine, Suwon, Korea). Goat
polyclonal anti-NeuroD antibody for western blot analysis
(N-19) and for supershift experiments and chromatin immuno-
precipitation assay (N-19X) and anti-HES1 antibody for ChIP
(N-17X) were purchased from Santa Cruz Biotech (Santa
Cruz, CA). Afﬁnity puriﬁed anti-MAP2ab was obtained
from Zymed Laboratories (San Francisco, CA), anti-a-
tubulin antibody was obtained from Sigma (St Louis, MO).
Horseradish peroxidase (HRP) conjugated goat anti-mouse
IgG was from Jackson Laboratories (West Grove, PA).
Anti-mouse IgG–FITC was purchased from Dako Corp.
(Carpentaria, CA).
Construction of human MAP2 promoter-luciferase
plasmids
Human MAP2 genomic sequence (GenBank accession no.
NT_005403) was identiﬁed using BLAST search with
MAP2 cDNA sequence, and a 2.2 kb region corresponding
 1854 to +368 was ampliﬁed by PCR using forward primer
50-CTGGCCTTTTTGGTTCTCAT and reverse primer 50-
TAGTCTAAGCTTAGC TGAGAATCTACCGA containing
HindIII sites and subcloned into the HindIII site of pGL3
basic vector. This plasmid is designated as phMAP2-2.
Since attempts to amplify the longer genomic DNA fragment
containing region upstream of  1854 were unsuccessful, we
ﬁrst PCR ampliﬁed a region corresponding to  2965 to  106
using a forward primer 50-GACGACAAGCTTCAGAAG-
AAGGGTAAGGCAAGCATCA and a reverse primer 50-
GACGACAAGCTTCGCAGTGGCGAACAGGAAAA, and
constructed the longer phMAP2-1 plasmid by joining the
50  2965/ 263 fragment with  263/+369 fragment at the
internal KpnI site. Deletion constructs phMAP2-3 ( 263/
+369) were made by splicing KpnI/KpnI ( 1854/ 268)
fragment out from phMAP2-2 and re-ligating the plasmid.
phMAP2-4 ( 269/+30) was made by digestion of
phMAP2-3 with PstI (+31) and HindIII (+368), followed by
ﬁll-in reaction with DNA polymerase (Klenow fragment)
and blunt end ligation.
E- and N-box mutant MAP2 promoters
mutE1 ( 2888/ 2883), mutE2 ( 2799/ 2794),
mutE3( 2304/ 2299), mutE4 ( 1593/ 1588) individual
mutations and various combination of E-box mutations
(E1,2,3,4; E1,2,3; E2,3) were generated in phMAP2-1,
mutN1 ( 961/ 956), mutN2 ( 63/ 58), mutE9 ( 358/
 353), mutE11 ( 279/ 274), mutE12 (+67/+72) and
mutE13 (+267/+272) and combinations of these mutations
(E12,13; E12,13,N1) were generated in phMAP2-2 using
the QuikChange site-directed mutagenesis kit (Stratagene,
La Jolla, CA) according to the manufacturer’s protocol. The
following primers were used for mutagenesis (only sense
sequence is given and mutated nucleotides within the
consensus sequence are underlined):
mutE1: 50-CACAGAAGTATCTACATGTTCGGTTGTC-
TTG; mutE2: 50-CTCCATGTTGGAAAGCATGCGGA-
AAAAAAGAAAAG; mutE3: 50-GATGATGGTGGCAG-
GTACACTCTTTTAGACATC; mutE4: 50-GGGAAAGAA-
AGTGTCTACGTGAGAGAAGAAAGG; mutE9: 50-CACA-
AAGGAGACGCGAGGATGACATTCATAG; mutE11:
50-GCCTGTCAGGGCTTCCGTACCAGAAG; mutE12:
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mutE13: 50-GAGTATAAAGAATGGGCTTGCCTTACTG-
GTGAG; mutN1: 50-CACTTAACCTCCCTAACCAGAGG-
CACTGTAAAATAG; mutN2: 50-GGCACACACAGAGCC-
GCCCTGGTGGCTTG CAG.
Transient transfection and luciferase assays
Transient transfections with various promoter constructs were
performed using Lipofectamine (Invitrogen, Carlsbad, CA)
according to the manufacturer’s instructions. Cells in 24- or
6-well tissue culture dishes, in triplicates, were trans-
fected with 0.6 or 3 mg, respectively, of empty vector pGL3
or promoter-reporter constructs (phMAP2-1, phMAP2-2,
phMAP2-3 and phMAP2-4) and 0.07 or 0.5 mg Renilla
luciferase plasmid pRL. In co-transfection experiments, dif-
ferent amounts of NeuroD and Hes1 expression plasmids
were added. For Notch1 inhibition and HES1 knockdown
experiments, cells were either pre-treated with indicated
amount of g-secretase inhibitor-DAPT (Calbiochem, La
Jolla, CA) and/or transfected with indicated amount of
lentiviral HES1shRNA plasmid (The RNAi Consortium
collection, a library of short hairpin DNAs cloned in
pLKO.1 lentiviral vector; Open biosystem, Huntsville, AL)
1 day before transfection with MAP2 promoter constructs.
After 48 h of transfection, cells were washed with pre-chilled
PBS and lysed in passive lysis buffer (Dual Luciferase kit,
Promega). Fireﬂy luciferase and Renilla luciferase activities
in the cell lysates were measured according to the manufac-
turer’s instructions using TD 20/20-luminometer (Turner
Biosystems, Sunnyvale, CA). Fireﬂy luciferase activity was
normalized to the Renilla luciferase activity and reported as
relative luciferase activity (RLA).
Transient transgenic expression
The 3.3 kb MAP2 genomic fragment from phMAP2-1 and
2.2 kb fragment from phMAP2-2 was isolated by digestion
with HindIII and subcloned into the HindIII site upstream
of Hsp68-lacZ gene in pHSF5 vector (21). The orientation
and sequences were conﬁrmed by restriction digestion
and sequencing. Transgenic embryos were generated by
Biotechnology Center (University of Wisconsin, Madison,
WI). Embryos harvested on day 11.5 were stained for
b-galactosidase activity essentially as described by
Shashikant et al. (21).
Immunostaining
Control embryos (11.5 days old) were ﬁxed in 4% formal-
dehyde overnight at 4 C and dehydrated using a graded series
of methanol, and embedded in parafﬁn. Sections (9 mm thick)
were cut and stained for MAP2 with anti-MAP2ab (Sigma)
using citrate buffer antigen retrieval method (22) followed
by anti-mouse IgG–HRP and the antigen was detected with
HRP substrate diaminobenzidene.
Electrophoresis mobility shift assay (EMSA)
Wild type E- and N-boxes containing oligonucleotides were
labeled with [g-
32P]ATP (3000 Ci/mMol; ICN Biomedicals,
Inc., Irvine, CA) with T4-polynucleotide kinase (Promega
Corp., Madison, WI). Unincorporated label was removed
using NAP5 columns (Amersham Pharmacia Biotech,
Piscataway, NJ). Radioactivity in the eluted fractions was
measured and  20000 c.p.m were used for each binding
reaction. The following reverse phase puriﬁed oligonucleo-
tides were annealed and used as probes and competitors.
Core sequences of E- and N-box are underlined: WtN1, 50-
CCTCCCTACACAAGGGCACTGT; mutN1, 50-CCTCCCT-
AACCAGAGGCACTGT; WtN2, 50-CACACACAGACAC-
GAGCTGGTGGCTT; mutN2, 50-CACACACAGAACCG-
GACTGGTGGCTT; mutN2-scrambled, 50-ACCAACCAGA-
ACCGGACTGGTGGCTT; WtE6E7, 50-GGGATATTCAA-
CTGCTAATTTCAGTTGCTAACATG; mutE6E7, 50-GGG-
ATATTACACGTCTAATTTACGTGTCTAACATG; WtE8,
50-AACATGGCCAAGTGCATAATTA; mutE8, 50-AACAT-
GGCACAGGTCATAATTA; wtE9, 50-AAGGAGACCAGA-
TGATGACATT; mutE9, 50-AAGGAGACACGAGTATGA-
CATT; wtE10, 50-TGGGGACACACTTGGATG GAGG;
mutE10, 50-TGGGGACAACCTGTGATGGAGG; wtE11,
50-GCCTGTCAGGCATTTGGTACCAGAAG; and mutE11,
50-GCCTGTCAGGGCTTCCGTACCAGAAG. Nuclear
extracts of COS-7 or cl.22a melanoma cells transfected
with Hes1 expression plasmid or with NeuroD expression
plasmid were prepared essentially as described previously
(16). Labeled probes were incubated with 5–10 mg of nuclear
extract at room temperature for 30 min. For supershift
experiments, anti-Hes1 or anti-NeuroD antibody or
unrelated polyclonal antibody were added to the reaction
mixture and incubated at room temperature for additional
30 min. DNA–protein complexes were analyzed by electro-
phoresis on non-denaturing 5% polyacrylamide gels run at
constant 200 V for 2 h in 0.5· TBE. The gels were dried
and exposed to X-ray ﬁlm (Eastman Kodak Company,
Rochester, NY).
Chromatin immunoprecipitation assay (ChIP assay)
Assay was performed using ChIP-IT kit (Active Motif, Carls-
bad, CA) following the manufacturer’s protocol. Brieﬂy, SK-
MEL-23 cells were cross linked, chromatin was prepared and
immunoprecipitated with anti-HES1 antibody (Santa Cruz) or
with control IgG. Then, immunoprecipitated DNA was eluted
and PCR ampliﬁed using appropriate primers. For PCR
ampliﬁcation of N1 (36 cycles) and N2 (29 cycles) box region
in MAP2 promoter region, the following primers were
used: N1-forward, 50-CCCAGGAAATAAATGCAGGA;
N1-reverse, 50-GGGCCGATATGTGATTTCTG; N2-
forward, 50-CCACTCGCCTTATTTTCCTG; and N2-reverse,
50-CGCATATGCAGCAAACAC. For PCR ampliﬁcation of
E9–E11 boxes (36 cycles) in promoter region the following
primers were used: forward, 50-TAAGCGGTGTGTGTG-
TGTGC; and reverse, 50-ATGATGACAAGCCACTCAGC.
RT–PCR
Total RNA was isolated from different melanoma and non-
melanoma cells using RNeasy Mini Kit (Qiagen, Valencia,
CA) and ampliﬁed by using one-step RT–PCR Kit (Qiagen)
as per manufacturer’s instructions using 100 ng of total
RNA and MAP2 forward primer 50-GCAGTTCTCAAAG-
GCTAGAC (nt 31–50 in MAP2ab cDNA in exon 3) and
reverse primer 50-TTGATCGTGGAACTCCATCT (nt 721–
740 in MAP2ab cDNA in exon 9).
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Total cell lysates of normal melanocytes, different melanoma
and non-melanoma cell lines were prepared using lysis buffer
[1% Triton X-100 in PBS containing cocktail of protease
inhibitors (Roche Diagnostics Corp., Indianapolis, IN)].
Protein was estimated using BCA protein assay kit (Pierce
Biotechnology Inc., Rockford, IL) and 50–100 mg protein
was separated on 9% SDS–PAGE, transferred on to
Polyscreen membrane (NEN Life Sciences, Boston, MA)
and the membranes were blocked and then incubated over-
night at 4 C with the primary antibodies diluted (anti-Hes1
at 0.6 mg/ml; anti-NeuroD at 1:250; anti-a-tubulin at
1:2000 and anti-b-actin at 1:2000) in 5% non-fat dry milk
in TBST, followed by incubation with the appropriate HRP-
conjugated secondary antibodies (at 1:5000 to 1:10000
dilution) for 1 h at room temperature. Protein bands were
detected by chemiluminescence using ECL kit (Amersham
Biosciences, Piscataway, NJ).
RESULTS
Nucleotide sequences upstream of MAP2 gene
are conserved in mouse, rat and human
Using BLAST search, we identiﬁed the human genomic
sequences upstream of MAP2 cDNA in a chromosome 2 con-
tig (GenBank accession no. NT_005403) and ampliﬁed, by
PCR, a 3334 bp genomic DNA fragment consisting 2965 nt
upstream of MAP2 transcription start site (+1), exon 1
(78 bp) and a part of intron 1 (291 bp). We sequenced this
fragment (GenBank accession no. DQ 386449), and cloned
it into pGL3 luciferase reporter vector (phMAP2-1;  2965/
+369). First, we analyzed this MAP2 genomic sequence for
transcription factor binding sites and compared the human
sequence with mouse and rat MAP2 genomic sequences
using CLUSTALW program (Figure 1A and B). This analysis
showed the following:
(i) Mouse, rat (GenBank accession nos: mouse,
NT_039170; and rat, NW_047816) and human MAP2
genomic sequences show 80% sequence identity in 1 kb
region corresponding to  691/+365 of human MAP2
genomic sequence. In addition, an 87 bp rat genomic
sequence showed 85% identity to human sequences
between  1388/ 1302. There were no homologous
sequences to this 87 bp in the mouse.
(ii) Inspection of the 3.3 kb human MAP2 50 genomic
sequence showed the presence of 13 (E1–E13) putative
E boxes (CANNTG) and two (N1 and N2) putative
N-boxes (CACNAG), which are potential sites for
binding bHLH proteins including neuronal transcrip-
tional activators and repressors (23,24).
(iii) The proximal cluster of three E boxes (E9–E11) at
 358/ 353,  313/ 308 and  279/ 274, and a N2 box
 63/ 58 found in the human MAP2 sequence are
conserved among mouse, rat and human sequences;
additional upstream (E1–E8) and downstream (E12 and
E13 within exon 1 and at +267/+272 within intron 1) E
boxes and N1 box at  961/ 956 within the human
MAP2 promoter sequence are not present in the mouse
and the rat MAP2 genomic sequences.
(iv) No canonical TATA box could be identified in the
MAP2 proximal 50 genomic sequences, suggesting that
MAP2 promoter is a TATA-less promoter (20,25,26).
MAP2 promoter activity
To investigate the promoter activity of MAP2 50 genomic
sequence, we generated, in addition to the 3.3 kb luciferase
reporter plasmid (phMAP2-1), 50 deletion constructs
phMAP2-2 ( 1864/+369), phMAP2-3 ( 263/+369) and a
30 deletion construct phMAP2-4 ( 263/+30) that lacks intron
1 sequence and part of exon 1. We tested the activity of these
MAP2 promoter plasmids in rat PC12 cells and human
teratocarcinoma cell line NT2/D1 by transient transfection
followed by luciferase assays. PC12 cells treated with NGF
are known to differentiate into neuron-like cells with neurite
outgrowths and express MAP2 (Figure 2A, inset) (17,18).
NT2/D1 is an inducible model system for neuronal differen-
tiation. Continuous culture of NT2/D1 cells in complete
serum containing retinoids or the addition of retinoic acid
to the steroid free culture medium is known to induce
neuronal differentiation and MAP2 expression (as shown by
RT–PCR, inset in Figure 2B) in these cells (27).
In NGF-treated PC12 cells, phMAP2-1 and phMAP2-2
promoter constructs showed 6- to 7-fold higher luciferase
activity compared with untreated cells. Although promoter
construct lacking sequences between  1854/ 263
(phMAP2-3) showed  2-fold higher basal activity compared
with phMAP2-1 and phMAP2-2 in untreated PC12 cells,
NGF treatment did not produce a signiﬁcant increase in the
Figure 1. (A) Schematic diagram of the 3.3 kb human MAP2 genomic
DNA fragment consisting 50 regulatory region, the first exon and
partial sequence of the first intron, and different promoter constructs used
in this study. The relative location (not drawn to scale) of putative E- and
N-boxes, and the transcription start site (arrow at +1) are shown. (B) Mouse
and rat genomic sequences homologous to the 3.3 kb human MAP2
promoter region were retrieved from GenBank database by BLAST search,
conserved E- and N-boxes region was aligned using CLUSTALW sequence
alignment program and shown by shading using Boxshade program. Dashes
show gaps in the sequences. Conserved E boxes and N2 box sequences are
highlighted.
3822 Nucleic Acids Research, 2006, Vol. 34, No. 13luciferase activity. In non-neuronal HeLa cells, all three
promoter constructs produced only weak luciferase activity
and treatment with NGF produced a 2-fold increase only in
cells transfected with the 3.3 kb phMAP2-1 promoter cons-
truct (Figure 2A). We found that luciferase activity driven
by the 3.3 kb MAP2-1 promoter was always lower than
that of the shorter 2.2 kb MAP2-2 promoter fragment in
every cell line tested, indicating the presence of negative
regulatory sequences between nt  2965 and  1854. There
are four putative E boxes (E1–E4) within this region of
MAP2 DNA. To test whether these E boxes play a role in
attenuating MAP2 promoter activity, we mutated E1, E2,
E3 and E4 boxes individually or in various combinations
including mutation of all four E boxes and tested the activity
of the mutant promoters. Mutation of neither individual E
boxes nor any combination of E boxes (including all four E
boxes) altered the basal activity of the 3.3 kb phMAP2-1
promoter (data not shown). These data suggested that the
distal E boxes do not contribute signiﬁcantly to the basal
activity of human MAP2 promoter and showed that the
2.2 kb genomic fragment  1854/+369 (phMAP2-2) was
sufﬁcient for maximal NGF-inducible, neuronal-selective
MAP2 promoter activity.
In NT2 cells cultured in complete medium, phMAP2-2 pro-
duced 150- to 200-fold higher luciferase activity compared
with the promoter-less pGL3-luc plasmid. Luciferase activity
in transfected NT2 cells was 15- to 20-fold higher than that
found in HeLa cells transfected with the same MAP2 pro-
moter construct (Figure 2B) conﬁrming the neuronal-
speciﬁcity of the 2.2 kb MAP2 promoter. We then tested
the activity of this MAP2 promoter in a representative
panel of primary and metastatic melanoma cells lines, and
human glioblastoma cell lines U138, U251 and a breast
cancer cell line, MCF-7. In phMAP2-2 transfected melanoma
cells, there was 20- to 30-fold higher luciferase activity
compared to cells transfected with promoter-less pGL3-Luc
(Figure 2C). Surprisingly, both primary and metastatic
melanoma cells showed signiﬁcant MAP2 promoter activity.
Although MAP2 promoter activity in melanoma cells was
lower than that found in NT2 cells, it was 4- to 6-fold
higher than that observed in HeLa cells or MCF-7 cells
(data not shown). MAP2 promoter activity was comparable
Figure 2. MAP2 promoter activity: activity of MAP2 promoter in PC12 (A), NT2/D1 (B) and melanoma cells (C). (A) Control and NGF-treated rat PC12 cells
and HeLa cells were transfected in triplicates in 24-well plates with the indicated MAP2 promoter-luciferase plasmids and the Renilla luciferase plasmid. Firefly
and Renilla luciferase activities were measured using Dual Luciferase Reporter Assay System (Promega). Data from a representative of at least three experiments
are shown as fold induction compared to the activity of promoter without NGF. Panels on right in (A) show immunostaining of control and NGF-treated PC12
cells with anti-MAP2 mAb. (B) Human teratocarcinoma cell line NT2/D1 (grown long term in medium containing serum) and HeLa cells were transfected with
the indicated MAP2 promoter constructs and luciferase activity was measured as described above. Data are shown as RLA (RLA ¼ 1). Error bars: means ± SEM.
Inset in (B) shows RT–PCR analysis of MAP2 mRNA expression in HeLa and NT2/D1 cells. Total RNA (100 ng) was used to perform RT–PCR (OneStep RT–
PCR kit; Qiagen) using primers that amplify a 709 bp fragment that spans human MAP2 exons 3–9. (C) Activity of phMAP2-2 in human primary and metastatic
melanoma cell lines. Luciferase activity was measured and data (means ± SEM) are shown as RLA.
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These data show that the neuronal-speciﬁc MAP2 gene
promoter is active in melanoma cells and are consistent
with the well-documented molecular plasticity and neural
differentiation of cutaneous melanomas (28,29).
MAP2 promoter activity in vivo
To verify that the cloned MAP2 genomic DNA fragments
show neuronal-speciﬁc expression in vivo, we tested their
activity by transient expression in transgenic mouse embryos.
Promoter fragments hMAP2-1 and hMAP2-2 were cloned
into b-galactosidase reporter construct pHHSF (21) and trans-
genic embryos were generated. Two independent sets of
transgenic embryos were created for each construct. Staining
of 11.5-day-old embryos with X-gal showed b-galactosidase
activity in 6 of 11 and 8 of 25 embryos produced by microin-
jection of hMAP2-1 and hMAP2-2, respectively. The X-gal
staining was restricted to developing central nervous system
including a weak staining of telencephalic vesicle and strong
staining of ventral mesencephalon, midbrain and hindbrain
junction (isthmus), rhombic lip and along the length of the
neural tube, developing eyes (Figure 3A). Both hMAP2-1
and hMAP2-2 transgenic embryos showed similar pattern
of staining. Staining of sections of parafﬁn embedded,
11.5-day-old littermate control embryos with anti-MAP2ab-
speciﬁc mAb M13 showed expression of endogenous
MAP2 protein in the same regions corresponding to those
where human MAP2 promoter driven b-galactosidase activity
was expressed (Figure 3A and B). These data show that
the 2.2 kb human MAP2 promoter also contains sequences
necessary for neuronal-selective expression in vivo.
Regulation of MAP2 promoter
Since MAP2 is a marker of neuronal differentiation, we
investigated the possibility that MAP2 promoter is regulated
by the key neuronal transcription factors. NeuroD/BETA2 is
a critical bHLH neurogenic factor that binds to a core 6 bp E
box element (CANNTG) as a heterodimer with a ubiquitous
partner E47 (30). HES1 is an important negative regulator of
neurogenesis (24). HES1 represses neuronal genes actively
by binding to N-box (CACNTG) as a homodimer or in a
dominant-negative fashion by forming heterodimers with
other bHLH factors that bind to E boxes (24,31).
A role of NeuroD in the regulation of MAP2 gene
promoter is indicated by the following observations: (i) in
neuroepithelial cells, induction of cell cycle arrest and
neuronal differentiation is associated with the activation of
NeuroD and MAP2 expression (32). (ii) MAP2 promoter
contains a consensus NeuroD-binding E-box (CAGATG)
found in other NeuroD target gene (33).
To test whether NeuroD activates MAP2 promoter, we
transfected HeLa cells and melanoma cells with MAP2
promoter plasmids phMAP2-1 or phMAP2-2 and increasing
amounts of NeuroD expression plasmid pNeuroD. As
shown in Figure 4A, co-transfection with pNeuroD produced
a dose-dependent increase in luciferase activity in both
phMAP2-1 and phMAP2-2 promoter transfected melanoma
cells. In HeLa cells, co-transfection of pNeuroD appears to
suppress the MAP2 promoter activity at lower dose but
stimulates it slightly at a higher dose. However, NeuroD-
stimulated MAP2 promoter activity in HeLa cells was signiﬁ-
cantly lower than its basal activity seen in melanoma cells
(Figure 4A).
Since the consensus NeuroD-binding E-box, E9 is con-
served between human and rodent MAP2, we ﬁrst tested
binding of NeuroD to E9 box sequences by electrophoretic
mobility gel shift assay. Incubation of nuclear extracts of
pNeuroD transfected (to enhance the sensitivity of the
assay) melanoma cells with
32P-labeled oligonucleotides
(22mers with a core E-box sequence CANNTG) showed
that the oligomer containing the E9 box (Figure 4B,
lane 1), but not E10 or E11 box (data not shown), produce
two DNA–protein complexes. Appearance of these
complexes, especially the slower migrating complex, was
inhibited in the presence of molar excess of wild-type cold
E9 oligonucleotide (Figure 4B, lanes 2 and 3). Addition of
molar excess of mutant E9 oligonucleotide with a core
sequence ACGAGT (lanes 4 and 5) or wild-type E10
oligonucleotide (lanes 6 and 7) produced only a slight inhi-
bition in the formation of slow migrating E9–protein
complex. Addition of anti-NeuroD antibody (lane 9) to
the reaction mixture completely prevented the formation of
these complexes, similar to the reported effect of this
antibody on binding of NeuroD to E boxes of other target
Figure 3. Human MAP2 promoter activity in vivo.( A) Whole-mount in situ
staining of 11.5-day-old pHSF-6/MAP2-1/lacZ promoter transgenic embryo
with X-gal for b-galactosidase gene expression. The b-galactosidase
expression is seen mostly in the developing central nervous system. TV,
telencephalic vesicle; VM, ventral mesencephalon; I, isthmus (midbrain–hind
brain junction) and rhombic lip; and NT, neural tube. Areas of the head and
the tail shown in (B) are indicated by red colored squares. (B) Paraffin
sections of head region and tail regions of 11.5-day-old littermate control
mouse embryos were stained with anti-MAP2ab mAb M13 (Zymed) (right
panels) or control IgG (left panels) using citrate buffer antigen retrieval
method followed by anti-mouse IgG–HRP and AEC detection method.
Endogenous MAP2ab protein expression is seen in regions of the embryo that
correspond to the region of X-gal staining. Upper panels: low magnification;
lower panels: high magnification of the areas indicated by red squares in the
upper panels.
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( 366/ 345) of MAP2 promoter.
We observed that a MAP2 promoter deletion construct of
pMAP2-3 ( 263/+369) that lacks all proximal E boxes,
including E9, still produced signiﬁcant luciferase activity
that was less than the maximal activity seen in cells trans-
fected with the 2.2 kb phMAP2-2 promoter plasmid. To test
whether this promoter constructs lacking the proximal E
boxes could still be activated by NeuroD, we transfected
HeLa cells and melanoma cells with phMAP2-3 plasmid and
with increasing amounts of pNeuroD. Surprisingly, co-
transfection with pNeuroD resulted in a dose-dependent
increase in luciferase activity of this MAP2 promoter in
melanoma cells but not in HeLa cells (Figure 5A). These
data suggest that although NeuroD can activate MAP2 gene
transcription by binding to E9 box, other factors that are con-
stitutively expressed in melanoma cells and those that may be
activated by NeuroD contribute to the transactivation of
MAP2 promoter. To test this, we generated 2.2 kb phMAP2-
2 promoter with mutations in the core sequence of E9 box
(CAGATG!GCGAGG), and compared its basal activity
with that of the wild-type promoter. As shown in Figure 5B,
mutation of E9 box resulted in nearly 50% decrease in
the basal luciferase activity. Additionally, this E9 mutant
phMAP2-2 promoter continued to exhibit a dose-dependent
activation by NeuroD (Figure 5C). Thus, NeuroD appears to
upregulate MAP2 promoter activity by both direct (by binding
to E9 box) and indirect mechanisms (presumably by activation
or induction of other trans-activators).
MAP2 promoter is inhibited by HES1
As mentioned earlier, HES1 is an important regulator of neu-
rogenesis and neuronal differentiation, Hes1 null mice
express both early and late neuronal markers including
MAP2 prematurely (36). To test whether MAP2 promoter
is regulated by HES1, we co-transfected NT2 cells and mel-
anoma cells (SK-MEL-19) with the 2.2 kb phMAP2-2
promoter and increasing amounts of mouse Hes1 expression
plasmid pCI-Hes1. In both NT2 cells (data not shown) and
melanoma cells, co-transfection with Hes1 resulted in a
dose-dependent inhibition of luciferase activity with a maxi-
mal (84%) inhibition at the highest dose of pCI-Hes1 plasmid
(Figure 6A). These data suggest a role for HES1 in the
regulation of MAP2 promoter activity.
The proximal N-box is necessary for
HES1-mediated repression
In phMAP2-2 promoter sequence, there are two putative
HES-binding motifs: N1 at  961/ 956 (CACAAG) and N2
Figure 4. Role of NeuroD/BETA2 in regulation of MAP2 promoter. (A) HeLa cells and metastatic melanoma cells c22a were transfected with indicated MAP2
promoter–reporter plasmids and either 25 or 100 ng of NeuroD expression plasmid pcDNA3-NeuroD1-FLAG or 100 ng of pcDNA3. Equal amount of total DNA
was used in all transfection. Luciferase activities were measured and RLA was calculated as described in the legend to Figure 1. Data shown are means ± SEM.
(B) Electrophoretic mobility shift analysis of E-box sequence.
32P-labeled double-stranded 22mer oligonucleotides with core sequence of E9 box CAGATG (see
Materials and Methods) were incubated with nuclear extract (5–10 mg protein) of c22a metastatic melanoma cells transfected with pNeuroD either alone or in the
presence of 5–50 M excess cold E9, E10 or mutant E9 oligonucleotides. Lanes 8 and 9 show mobility shift pattern after the addition of control rabbit IgG (lane 8)
or rabbit anti-NeuroD antibody (lane 9) to the E8 oligonucleotide–protein complexes.
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N-boxes in repression of MAP2 promoter activity by HES1,
we tested whether mutation of either one or both N-boxes
increases basal activity of the promoter and/or makes it less
sensitive or refractory to repression by HES1. In melanoma
cells transfected with the mutant phMAP2-2 promoter plas-
mids, there was a modest but signiﬁcant increase (26%
over wild type) in the luciferase activity driven by the
mutN2 (CACGAG!GCCGCC) and mutN1N2 promoters
(P < 0.05), and a smaller increase (10% over wild type) in
the activity driven by the mutN1 (CACAAG!ACCAGA)
MAP2 promoter (Figure 6B). In addition, co-transfection
with pCI-Hes1, which resulted in 60% inhibition of luciferase
activity driven by the wild-type and mutN1 promoters, pro-
duced signiﬁcantly less inhibition of mutN2 and mutN1N2
promoter activities (Figure 6C, P < 0.05 and P < 0.01, respec-
tively). These data suggest that N2 box is involved in HES1-
mediated repression of MAP2 promoter. In addition to its
action by direct binding to N2 box, HES1 is also known to
act indirectly by making non-functional heterodimers with
transcription activators that bind to E boxes (37). Whereas
the 2.2 kb MAP2 minimal promoter contains two potential
HES-binding N-boxes, the 293 bp phMAP2-4 promoter
deletion construct that we generated contains only the proxi-
mal N2 box. Transfection of melanoma cells with phMAP2-4
promoter-luciferase plasmid and Hes1 expression plasmid
showed that Hes1 was able to repress the activity of
phMAP2-4 promoter containing only the proximal N-box
(Figure 6D), conﬁrming that the regulation of MAP2
promoter by HES1 is mediated primarily by this proximal
N2 box at  63/ 58.
To test whether HES1 binds to N2 sequence, we performed
electrophoretic mobility shift assay. As shown in Figure 6E,
Hes1 transfected melanoma nuclear extracts retarded the
mobility of N2 box oligonucleotides. Addition of a molar
excess of cold wild-type N2 box DNA resulted in a complete
inhibition of the mobility shift of the labeled N2 box oligo-
nucleotide. In some experiments, we also observed a second,
faster migrating and non-speciﬁc complex (Figure 6E,
asterisk on the left), which could not be competed out by
molar excess of cold N2 box DNA. The presence of molar
excess wild-type N1 box or mutant N2 box oligonucleotides
in the reaction resulted in only a slight decrease in the
formation of this N2 DNA–protein complex (Figure 6E).
The addition of anti-Hes1 antibody, but not control rabbit
IgG, to the reaction caused further retardation of the N2
box–protein complex. However, addition of these antibodies
to N2 DNA–protein complex showed two additional non-
speciﬁc complexes (Figure 6E, asterisks on the right).
These data showed that HES1 represses MAP2 promoter
activity by binding preferentially to the proximal N2 box
sequence.
HES1 is a dominant regulator of MAP2
promoter activity
Neuronal differentiation is known to be regulated by the
relative levels of pro-neuronal transcription factors and
repressors neuronal-speciﬁc genes (38). To investigate the
relative contribution of NeuroD and HES1 in the regulation
of MAP2 promoter activity, we co-transfected melanoma
cells with phMAP2-2 and (i) constant amount of NeuroD
expression plasmid and increasing amounts of pCI-Hes1
plasmid or (ii) a constant amount of pCI-Hes1 plasmid and
increasing amounts of pNeuroD plasmid. In melanoma
cells, co-transfection with pNeuroD alone resulted in  50%
increase in luciferase activity driven by phMAP2-2 promoter,
and transfection of the promoter with pCI-Hes1 resulted in
60% inhibition in promoter activity. Transfection with
increasing amounts of pCI-Hes1 along with constant amount
of pNeuroD that produces 50% increase in promoter activity,
not only prevented the pNeuroD-dependent increase but also
produced a dose-dependent decrease in the promoter activity
(Figure 7A). In contrast, co-transfection of increasing
amounts of pNeuroD, which upregulated MAP2 promoter
activity when present alone, was unable to relieve the inhibi-
tion of the promoter activity caused by HES1 (Figure 7B).
These data suggest that HES1 is a dominant regulator of
MAP2 promoter activity in human melanoma cells.
To test whether melanoma cells express these neuronal
transcription factors and whether variable MAP2 promoter
activity in different melanoma cell lines might be related to
relative levels of these factors, we performed western blot
Figure 5. Indirect activation MAP2 promoter by NeuroD. (A) HeLa cells and
metastatic melanoma cells c22a were co-transfected with phMAP2-3
promoter-reporter plasmid lacking the E9 box and NeuroD expression
plasmid pcDNA3-NeuroD-FLAG (pNeuroD) (25 and 100 ng) or 100 ng of
control pcDNA3 vector. (B) Effect of mutation of the core E9 box sequence
(CAGATG!ACGAGT) on MAP2 promoter activity. Asterisk indicates P-
value (Student’s t-test, P < 0.001). (C) Dose-dependent activation of mutE9-
phMAP2-2 promoter by NeuroD. c22a melanoma cells were co-transfected
with mutE9 phMAP2-3 and increasing amount of pNeuroD plasmid. Equal
amounts of total DNA were used in all transfections. Luciferase activities
were measured and RLA (means ± SEM) was calculated as described in the
legend to Figure 1.
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shown in Figure 7C, whereas variable amounts of NeuroD
expression could be detected in both melanocytes and mela-
noma cells, HES1 expression is detectable only in melanoma
cells. These observations support the RT–PCR data reported
by Balint et al. (39), who showed that HES family mRNAs
(speciﬁcally HES1) are expressed in melanoma cell lines
but not in melanocytes. There was no clear relationship
between the levels of NeuroD and HES1 among different
melanoma cell lines.
To test whether endogenous NeuroD and HES1 proteins
in melanoma cells bind to MAP2 promoter sequence, we
performed chromatin immunoprecipitation assays
(Figure 7D). Sheared chromatin was immunoprecipitated
with anti-NeuroD and anti-Hes1 antibodies or with control
IgG, followed by PCR ampliﬁcation of the corresponding
regions of DNA using speciﬁc primers. Analysis of ampliﬁed
DNA (Figure 7D) showed that immunoprecipitation with
anti-Hes1 antibody enriched (compared to control IgG
precipitation) sequences that are ampliﬁed preferentially by
primers ﬂanking N2 box compared to primers ﬂanking N1
box. Ampliﬁcation of anti-NeuroD immunoprecipitated
chromatin did not show any marked enrichment of seq-
uences ampliﬁed by primers ﬂanking E9–E11 region. These
data show that endogenous HES1 protein in melanoma
cells binds to MAP2 promoter region, and suggest that
HES1 acts as a dominant factor in regulating MAP2 promoter
activity.
Figure 6. HES1 (hairy and enhancer of split) represses MAP2 promoter activity. (A) Human metastatic melanoma cells were transfected with 2.2 kb phMAP2-2
promoter and increasing amounts (0.1, 0.3 and 0.6 mg) of mouse Hes1 expression plasmid pCI-Hes1 or 0.6 mg the empty vector pcDNA3. Forty-eight hours after
transfection luciferase activities were measured. RLA were calculated and MAP2 promoter activity in Hes1 expressing cells is shown as percent (means ± SEM)
of pcDNA3 co-transfected cells. (B) Mutational analysis of the role of N-boxes in repression of MAP2 promoter by Hes1. Metastatic melanoma cells were
transfected with wild-type (wt) and N-box mutated (mutated nucleotides shown underlined) phMAP2-2 promoter plasmids mutN1 (ACCAGA), mutN2
(GCCGCC) and mutN1N2 and luciferase activity in cells transfected with mutant plasmids is shown as percent of wild-type transfected cells (*P < 0.05
compared with wt; one-way ANOVA). (C) Metastatic melanoma cells were transfected with wt and N-box mutant plasmids together with 1.5 mg empty vector
pcDNA or pCI-Hes1 plasmid and luciferase activities in cell lysates was measured 48 h after the transfection. Repression of the wild-type and N-box mutant
promoter activity by Hes1 is shown as percent activity of wild-type and the mutant plasmids in cells transfected with the pcDNA empty vector (*P < 0.05; **P <
0.01 compared with wt; one-way ANOVA). (D) Repression of the phMAP2-4 ( 263/+30) promoter by Hes1. Melanoma cells in 24-well plate were transfected,
in triplicates, with 0.6 mg phMAP2-4 plasmid and 0.6 mg of empty vector pcDNA or indicated amounts of pCI-Hes1 plasmid. After 48 h transfection, cells were
lysed and RLA was determined. MAP2 promoter activity in the presence of Hes1 is shown as percent of empty vector transfected cells. Equal amount of total
DNA was used in all transfection. Data (mean ± SEM) shown are representative of least three experiments. (E) Electrophoretic mobility shift analysis of N-box.
32P-labeled N2 box double-stranded oligonucleotides were incubated with nuclear extract (5–10 mg protein) of pCI-Hes1 transfected c22a metastatic melanoma
cell either alone or in the presence of 5–50 M excess cold N1, N2 or mutant N2 box oligonucleotides or a polyclonal Hes1 antibody or a control rabbit IgG. Left
arrow indicates the specific N2 box DNA–protein complex and the right arrow indicates the Hes1 supershifted complexes. Asterisks indicate non-specific
complexes.
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activity in melanoma cells
To test the effect of Notch1 signaling, a regulator of HES1
expression, on MAP2 promoter activity in melanoma cells,
we treated primary and metastatic melanoma cells with g-
secretase inhibitor, DAPT (which inhibits the cleavage of
intracellular domain of Notch1 and hence Notch1 signaling)
and/or transfected with HES1shRNA. In primary melanoma
cell line WM35, a dose-dependent increase in MAP2 promoter
activity was observed with increasing dose of g-secretase
inhibitor (Figure 8A). Transfection with HES1shRNA or
transfection followed by treatment with g-secretase inhibitor
also caused similar activation of MAP2 promoter. In contrast,
treatment with g-secretase inhibitor alone was not sufﬁcient to
activate MAP2 promoter in metastatic melanoma cell line
451Lu. Transfection with HES1shRNA alone or transfection
with HES1 shRNA followed by treatment with g-secretase
inhibitor was able to upregulate MAP2 promoter activity in
these cells (Figure 8B). Treatment with DMSO or transfection
with control shRNA did not signiﬁcantly affect MAP2 pro-
moter activity and were used as controls. Westernblot analysis
showed that transfection with HES1shRNA alone or treatment
of shRNA transfected cells with DAPT decreased the level
of HES1 more effectively in primary melanoma cells than
in metastatic cells (Figure 8C). Although we did not
observe a marked reduction in HES1 levels in shRNA
transfected 451Lu cells, there was  2-fold increase in
MAP2 promoter activity indicating that MAP2 promoter
may be sensitive to small changes in HES1 levels. These
data suggest that primary melanoma cells are more sensitive
to Notch1 inhibition and MAP2 promoter upregulation
than metastatic melanoma cells and are consistent with earlier
published observations (14).
DISCUSSION
Human cutaneous melanoma is known to exhibit molecular
plasticity and often express genes characteristic of neural
cell lineages (11,28). Our observation that MAP2 is activated
in vivo during early stages of melanoma tumor progression,
and that NeuroD can upregulate MAP2 promoter activity
preferentially in melanoma cells in vitro are consistent with
a well-documented tendency of melanoma, a tumor that origi-
nates from the neural crest-derived melanocytes, to exhibit
Figure 7. HES1 is a dominant repressor of MAP2 promoter activity. (A) Melanoma cells were transfected with phMAP2-2 promoter-luciferase plasmid alone, or
with Hes1 expression plasmid pCI-Hes1 or NeuroD expression plasmid pcDNA3-NeuroD-FLAG. In addition, 0.1 and 0.3 mg of Hes1 expression plasmid pCI-
Hes1 was included in cells co-transfected with NeuroD. (B) c22a melanoma cells were transfected with phMAP2-2 promoter-luciferase plasmid alone, or with
Hes1 expression plasmid pCI-Hes1 or NeuroD expression plasmid pcDNA3-NeuroD-FLAG. Cells in additional wells transfected with pCI-Hes1 also received
0.1 or 0.3 mg of pNeuroD plasmid. Equal amount of total DNA was used in all transfection. Luciferase activities were measured and the promoter activity in cells
co-transfected with either pcDNA3-NeuroD or pCI-Hes1 alone or with increasing amounts of pCI-Hes1 or pcDNA3-NeuroD1, respectively, is shown as
percentage (means ± SEM) of activity in cells transfected with phMAP2-2 and pcDNA. (C) Expression of NeuroD and HES1 in melanocytes and melanoma
cells. Western blot analysis of NeuroD expression in control and pcDNA3-Neuro-FLAG plasmid transfected COS cells, neonatal foreskin melanocytes (NMC),
primary melanoma cell line WM75 and various metastatic melanoma cell lines. Seventy-five micrograms of detergent soluble total cellular proteins were
separated by SDS–PAGE and immunoblotted with polyclonal goat anti-mouse NeuroD (upper panel) and anti-mouse Hes1 antibody (lower panel), followed by
HRP-conjugated secondary antibody. Protein bands were detected by chemiluminescence. Western blotting for a-tubulin is shown as a control for protein
loading. (D) Chromatin immunoprecipitation assay. Sheared chromatin from melanoma cells was immunoprecipitated (IP) with appropriate antibody (anti-HES1,
anti-NeuroD or control IgG) and antibody bound DNA was isolated according to the manufacturer’s protocol (Active Motif, Carlsbad, CA). Immunoprecipitated
DNA was used as template in PCR using N1 and N2 primer (for HES1), E9–E11 primer (for NeuroD). GAPDH primers were used as control.
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ferentiation of melanoma can alter the biology of the tumor
and, hence, the clinical outcome in patients. We showed
that aggressiveness of primary melanoma in vivo is inversely
correlated with MAP2 expression and that overexpression of
MAP2 in metastatic melanoma cells in vitro results in cell
cycle arrest and growth inhibition (12). In these studies
aimed at understanding the mechanisms involved in the
activation of MAP2 gene in melanoma cells, we identiﬁed
the 50 regulatory region of human MAP2 gene and show
that MAP2 promoter is regulated by neuronal bHLH factors
NeuroD and HES1, and HES1 acts as a dominant regulator
of MAP2.
Human MAP2 promoter
Transcriptional regulation of genes that encode members of
the microtubule-associated proteins, MAP1A, MAP1B and
tau, has been investigated (40–44). Interestingly, promoter
sequence of MAP2 gene does not share any common features
with other MAP genes. Our data show that MAP2 promoter
that supports tissue-speciﬁc activity both in vitro and
in vivo contains multiple bHLH binding sites. We also show
that MAP2 promoter is regulated by the neuronal bHLH tran-
scription factors consistent with the wide use of MAP2
expression as marker for neuronal differentiation. Neuron-
speciﬁc activity of promoters of other MAP genes is less
well deﬁned. For example, a 2.4 kb 50 region of mouse
MAP1A, which contains two TATA-less promoters and one
Sp1 site that regulate the expression of two alternative tran-
scripts, was shown to be active in both neuronal and non-
neuronal cells. Rat and human MAP1B promoter sequences,
however, contain a consensus element known as ‘neuronal
motif’ (common to several neuronal genes such as GAP43,
perinephrin and neuroﬁlament), a Sp1 site, a TCC repeat
and a cAMP response element. However, none of these ele-
ments appears to be necessary for neuron-speciﬁc MAP1B
promoter activity (42). Similarly, although promoters for
Figure 8. Notch1 signaling is involved in MAP2 promoter regulation in melanoma cells. Primary melanoma cells, WM35 (A) and metastatic melanoma cells,
451Lu (B) were either pre-treated with 1 or 2 mM g-secretase inhibitor (DAPT) or transfected with 0.6 mg of HES1shRNA and then treated with 2 mM DAPT.
After 24 h, the cells were transfected with phMAP2-2 luciferase-promoter construct. Cells were lysed and luciferase activity was measured 48 h after promoter
transfection. RLA was calculated as described in the legend to Figure 2. Data are shown as percent activity of control DMSO-treated cells or control shRNA
transfected cells, and are from a representative of two individual experiments with triplicates. (C) Western blotting analysis of primary (WM35) and metastatic
(451Lu) melanoma cells transfected with HES1shRNA alone or in combination with the treatment of DAPT, show decreased level of endogenous HES1 protein.
Western blotting of b-actin is shown as loading control.
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sensus elements for neuron-speciﬁc expression were deﬁned.
A distinguishing feature of MAP2 promoter is the presence
of multiple E boxes, which are known to be recognized by
bHLH factors including those that participate in the regula-
tion of cell and tissue-speciﬁc gene expression. Presence of
E boxes is consistent with neuronal differentiation-speciﬁc
expression of MAP2. Among the E boxes in the MAP2
promoter, a cluster of three proximal E boxes (E9–E11) are
of particular interest because (i) they are strictly conserved
among mouse, rat and human, including their relative dis-
tance from the transcription start site and spacing between
the boxes and (ii) the distal E-box (E9) within this composite
element contains a NeuroD-binding sequence CAGATG,
identical to that found in well-characterized NeuroD target
gene rat glucagon (33). Other known NeuroD target genes
that also contain a cluster of three or four E boxes in their
proximal promoter regions are insulin and insulinoma-
associated antigen 1, Pax6 and sulfonylurea receptor I
(20,30,35,45). A comparison of NeuroD-binding E boxes of
these genes (including MAP2) showed that NeuroD
preferentially binds to the sequence CAN(A/G/T)NTG.
Other E-box-like elements (CACNTG) found within this
cluster do not appear to be functional with respect to NeuroD
(33,45). Mutational analysis of E9, E10 and E11 boxes of
MAP2 promoter and gel-shift data presented in this study
also support these earlier published observations.
Neuronal differentiation is known to be regulated not only
by transcriptional activators but also by HES and Id family of
repressors (46–48). Among these repressors, the role of HES1
has been extensively investigated. For example, neuronal
precursor cells infected with HES1-transducing retrovirus
do not differentiate into neurons and fail to activate expres-
sion of neuronal markers (49), and Hes1 null mice express
both early and late neuronal markers, including MAP2,
prematurely (36). HES family repressors can inhibit gene
expression either directly by binding (as homodimers) to
their cognate-binding elements known as N-boxes (CAC-
NAG) or indirectly by dominant-negative regulation (by
forming non-functional heterodimers with transcriptional
activators). To our knowledge, rat and human achaete-scute
homolog-1 (MASH1), HES1 and E2F1 are the only genes
shown to be directly repressed by binding of HES1 to the
respective promoters (50–53). In HES1 proximal promoter
there are three N-boxes and all three have been shown to
bind HES1 and contribute in the autoregulation of HES1
expression (51). E2F1 promoter has a single N-box and bind-
ing of HES1 to this element appears to inhibit estrogen and
heregulin-mediated upregulation of E2F1 in breast cancer
cells (52). On the other hand, hASH1 promoter contains a sin-
gle HES1-binding class C site with a core sequence
CACGCA (50). In human MAP2 promoter, we identiﬁed
two putative N-boxes, a distal CACAAG (N1) and a proximal
CACGAG (N2) box. We showed, by mutational and gel-shift
analysis, that the proximal N2 box is involved in HES1-
mediated regulation of the promoter activity. Interestingly,
these N-boxes are not present in the mouse and rat MAP2
promoters, although a N-box-like CAGGAG element,
conserved between the mouse and the rat MAP2, is found
at a position similar to that of human MAP2 promoter.
However, the role of this N-box-like sequence in the
regulation of MAP2 expression in these species remains to
be investigated.
Our data show that MAP2 gene contains both positive
(E boxes) and negative (N-boxes) regulatory elements and
suggest that MAP2 expression might be regulated by a
balance between positive and negative bHLH factors
NeuroD and HES1. This is consistent with the proposal that
transition of neuronal precursor cells from proliferation to
neurogenesis involves coordinate increase in the pro-neural
bHLH factors and a decrease in the activity of HES and Id
factors (38). It is tempting to speculate that in vivo MAP2
gene might be regulated by a balance between NeuroD and
HES1. For example, in rat insulinoma InR1G9 cell line, insu-
lin gene (a NeuroD target) has been shown to be regulated by
the ratio of NeuroD and the transcription repressor Id1 (33). It
is therefore possible that variable levels of MAP2 promoter
activity in melanoma cell lines may be due to variable ratio
of NeuroD and HES1, as both factors are expressed in all
melanoma cell lines tested. In this context, it is of interest
to note that whereas transfection with increasing amounts
of Hes1 plasmid produced a dose-dependent decrease of
NeuroD activation of MAP2 promoter, transfection with
increasing amount of NeuroD was unable to relieve the
repression of the promoter by Hes1. Thus, MAP2 promoter
activity seems to be regulated predominantly by HES1 levels.
This possibility is also supported by the results of the ChIP
assay, which showed that in melanoma cells N-box region
of MAP2 gene promoter is occupied by endogenous HES1
protein. Further, reducing endogenous HES1 protein level
in melanoma cells using HES1shRNA was also able to
increase the basal activity of MAP2 promoter.
It is also relevant to note that Notch1 signaling, which
activates HES1 gene expression, has been shown to be
elevated in melanoma cells (54,55). It has also been shown
that the activation of Notch1 signaling is required for
b-catenin-mediated human primary melanoma progression
and that primary melanoma cells are more sensitive to
Notch1 inhibition than metastatic cells (39). Our data, using
Notch1 inhibitor, indicate an involvement of Notch1 signal-
ing via HES1 in the regulation of MAP2 gene expression.
In agreement with published data (15), we found that primary
melanoma cells are more responsive than metastatic cells to
inhibition of Notch1 signaling and MAP2 promoter upregula-
tion. These data are also consistent with our earlier ﬁndings
that MAP2 is expressed more frequently in primary lesions
(11,12). Thus, blocking of Notch1 signaling and/or HES1
may be considered as useful therapeutic strategy for mela-
noma treatment. However, our preliminary ﬁndings on induc-
tion of endogenous MAP2 gene expression suggest that in
addition to regulation by Notch signaling, MAP2 gene is
also regulated by epigenetic mechanisms (Nityanand
Maddodi, Kumar M. R. Bhat and Vijayasaradhi Setaluri,
unpublished data), indicating a tight regulation of this gene
during melanoma progression.
In summary, our ﬁndings on the regulation of neuronal
MAP2 promoter gene in melanoma cells are relevant to
understanding molecular mechanisms of melanoma progres-
sion. A more detailed understanding of the regulation of
MAP2 gene transcription in melanoma cells might allow us
to design and develop strategies that can activate this gene
as a novel therapeutic approach for malignant melanoma.
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